Tumor profiling test for breast cancer

with hormone receptor-positive (ER+), HER2 (human epidermal growth factor receptor 2) negative breast cancer, when considering the initiation of chemotherapy. The test should provide both a predictive and prognostic tool to estimate a patient’s risk of distant breast-cancer recurrence. The tumor pr

ofiling test must demonstrably improve the risk classification of patients and identify those patients who will benefit the most from chemotherapy.